Home Featured Page 174

Featured

Latest

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global...

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S....

PT351 – Seth Rosenberg – The Trauma In Being Arrested and...

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Wesana Announces Second Quarter 2022 Financial Results

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

MindMed Completes 1-for-15 Reverse Share Split

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global...

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S....

PT351 – Seth Rosenberg – The Trauma In Being Arrested and...

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Wesana Announces Second Quarter 2022 Financial Results

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

MindMed Completes 1-for-15 Reverse Share Split

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY